On May 30, the European Commission granted marketing authorization for FLIXABI,® an infliximab biosimilar developed by Samsung Bioepis, the joint venture between Biogen and Samsung Biologics. See here for press coverage.
Related Content
- Big Molecule WatchMarch 27, 2024
Biden Administration Proposes Biosimilar Substitution Without Interchangeability
- Big Molecule WatchMarch 22, 2024
Women’s History Month Spotlight: Emmanuelle Charpentier and Jennifer Doudna
- Big Molecule WatchMarch 19, 2024
Celltrion Announces Commercial Availability of ZYMFENTRA™ (infliximab-dyyb)
- Big Molecule WatchMarch 19, 2024
Updates on Aflibercept BPCIA Litigation
- Big Molecule WatchMarch 18, 2024
Celltrion Submits BLA for Omalizumab Biosimilar
- Big Molecule WatchMarch 15, 2024
Fresenius Kabi Announces FDA Approval of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRA
- Big Molecule WatchMarch 8, 2024
FDA Approves Sandoz Denosumab Biosimilars
- Big Molecule WatchMarch 7, 2024
Biocon Settles with Bayer and Regeneron, Securing Canada Market Entry Date for Aflibercept Biosimilar
- Awards and RankingsSeptember 25, 2023
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year
- Awards and RankingsOctober 4, 2022
LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences
- Press ReleaseNovember 17, 2021
Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.
- Awards and RankingsOctober 26, 2021
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year
- Press ReleaseJune 28, 2021
Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson
- EventsDecember 5, 2020
China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?
- Awards and RankingsOctober 5, 2020
Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year
- Speaking EngagementsSeptember 23, 2020
ACI's 11th Summit on Biosimilars & Innovator Biologics